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The COVID-19 pandemic has focused on the acute respiratory phase of SARS-CoV-2 infection which has killed
over three million people globally [1]. Attention is now increasing on the serious long-term, multi-organ illness
occurring after COVID-19 infection: Long Covid. Long Covid symptoms include: extreme fatigue; insomnia;
headaches; lung, kidney and cardiac damage; and muscle and joint pain. These debilitating symptoms affect
individuals who have had both mild and severe acute COVID-19 and are estimated to affect five million people
globally. Long Covid awareness originated from Long Covid patients, known as long haulers, finding each other
on social media and support groups. Long hauler patient activism has been the driving force behind Long
Covid recognition, research and health policy development. Two support groups have played key roles: The
Body Politic COVID-19 Support Group and The Long Covid Patient Support Group. These bodies have raised
awareness of Long Covid in the media, and in academic and medical communities. They have also provided
support for long haulers. The Body Politic COVID-19 Support Group produced a patient-led research report
which catalysed research policy for Long Covid. Peer-reviewed research has revealed a diverse array of severe,
multi-organ symptoms of Long Covid and has recommended a multi-disciplinary healthcare approach to Long
Covid. This recommendation has been adopted by various governments and medical institutions, which have
opened Long Covid clinics. Population morbidity from Long Covid is a rising challenge, requiring research, a
multi-disciplinary healthcare approach and socio-economic support.
Science ⇒ Policy
Long Covid is a serious multi-organ long-term illness that occurs in individuals after severe and mild COVID-19
infection. Population morbidity from Long Covid is a rising challenge, requiring; research, multi-disciplinary
healthcare approaches and socio-economic support. Long Covid recognition, research and health policy has
been driven by patients and patient activism.
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Introduction
Over three million people have died globally
from the acute respiratory illness COVID-19 and
many more are currently suffering serious, long-
term symptoms following COVID-19 infection [2].
Long Covid, also known as post-Covid syndrome,
has no widely accepted clinical definition. There
is general consensus that Long Covid consists of
the ‘signs and symptoms that develop during or
after an infection consistent with COVID-19’ [3].
It is the duration of symptoms after initial infec-
tion that is debated. Some research studies use
the definition of symptoms beyond three weeks
post infection [4, 5], while the recent UK Na-
tional Institute for Healthcare Excellence (NICE)
guidelines use 12 weeks [3]. The lack of a precise,
clinically accepted definition is indicative of our
developing understanding of Long Covid. Long
Covid research is still in its infancy and further
investigation is necessary to reach a clinical defi-
nition. This article explores the development of
Long Covid policy in two main areas: research
and healthcare policy, with emphasis on the role
of patients and patient activism.
Many viruses can cause long-term illness, such as
the Epstein Barre virus which causes infectious
mononucleosis (commonly known as glandular
fever) and influenza which can cause post-viral
fatigue. What makes COVID-19 unique is the
‘sheer number of infected people and the dam-
aging effects of infection on multiple organ sys-
tems, including the lungs, liver, brain, kidneys
and heart’ [6]. Long Covid ‘is the other side of
COVID: the long haulers that could turn out to
be a bigger public health problem than excess
death from COVID-19’ [7]. With estimates of
millions of long haulers globally dealing with de-
bilitating symptoms and associated increasing
population morbidity, it is important that we un-
derstand the scope and impact of Long Covid in
order to develop good research and health and
socio-economic policies. The driving force be-
hind Long Covid policy and recognition has, so
far, been patients and their collectivised support
groups.
Long Covid was coined by Italian patient and
doctor Elisa Perego on Twitter [8], and has since
been adopted by patients and patient support
groups to describe their long-term symptoms af-
ter an initial COVID-19 infection [9]. Patients
who had previously suffered from a COVID-19
infection or COVID-19 like infection, and were ex-
periencing long-term symptoms, found each other
on social media. They collectivised in online
support groups as long haulers and together char-
acterised their illness, Long Covid. Long haulers
have worked hard to raise awareness of Long
Covid in the media, within academic and med-
ical institutions, and within governmental and
intergovernmental organisations. Long haulers
and their support groups have been the dominant
driving force behind Long Covid policy.
Long Covid Support Groups
and Patient Activism
Patients and patient activism have always con-
tributed to disease recognition and policy devel-
opment. Long Covid is unique because patients
have defined, researched and raised awareness
of Long Covid alone, gaining recognition, sup-
port and research into their illness in the process.
They have achieved this through the actions of
prominent individuals and collectivisation in on-
line support groups. There are many COVID-19
support groups, but this article focuses on ‘The
Body Politic COVID-19 Support Group’ [10] and
the ‘Long Covid Support Group’ [11]. Other
COVID-19 support groups include the respira-
tory focused ‘Coronalong Square Group’ in the
Netherlands [12], and the ‘Survivor Corps’ in the
United States [13]. The Body Politic COVID-
19 Support Group and the Long Covid Support
Group are two of the first and largest groups,
having made the greatest impact in progressing
Long Covid Policy. These groups have: produced
compelling Long Covid testimonials in the me-
dia; generated a large, coordinated social media
presence, reaching out to long haulers globally;
engaged with medical and research institutions,
and produced the first report on Long Covid.
The initial awareness of Long Covid within the
mainstream media and academic and medical re-
search communities came from patient activists.
The Body Politic COVID-19 Support Group was
founded by long haulers Fiona Lowenstein and
Sabrina Bleich in March 2020 and has grown to
include over 18,000 individuals [10]. The organ-
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isation includes online support for all COVID-
19 patients that have suffered from both acute
and Long Covid, as well as carers and loved
ones. The organisation started in New York and
has grown to include members from all over the
globe. Fiona Lowenstein was one of the first to
publish a Long Covid testimonial in an opinion
piece in the New York Times [14]. The Long
Covid Support Group, with 33,200 members, was
founded by Clare Hastie [11] and is most active
in the UK. When these groups were set up, they
were the only support available to long haulers.
They gave long haulers the opportunity to share
and learn from each other and receive validation
that has mostly been unavailable from health-
care providers. ‘Long Covid is the first illness
to be made through patients finding one another
on Twitter and other social media’ [9]. These
support groups have continued to grow as the
number of long haulers increases rapidly during
this pandemic.
The support groups and prominent individuals
reached out to academia and mainstream me-
dia to raise awareness of the new phenomenon
that is Long Covid. The individual testimonies
from long haulers with prominence in the medical
fields played a crucial role in raising Long Covid
awareness in scientific and medical communities.
Professor Paul Garner, professor of infectious dis-
eases, published his personal account of Long
Covid in the British Medical Journal [15]. It has
been made clear that ‘patient-made evidence in
the form of one case study was important when no
peer-reviewed articles had yet documented long-
lasting symptoms. Non-hospitalised patients were
at that point, literally beyond the gaze of biomedi-
cal research’ [9]. Medical professional long haulers
have been active in campaigning government and
medical institutions [16]. ‘Doctors as patients,’ a
group in the UK, published a manifesto calling
for ‘collaboration between politicians, healthcare
services, public health professionals, scientists
and society’ to tackle Long Covid [17]. Doctors
were particularly effective at reaching out to long
haulers globally in their mainstream media ap-
peals, giving long haulers a sense of community,
and helping them to understand their symptoms
[18]. Consequently, Long Covid started to be
acknowledged on the healthcare, academic and
media horizon.
Long haulers have shared their experiences and
symptoms in social media based support groups,
revealing Long Covid as an illness that extends be-
yond a short acute respiratory phase and includes
serious multi organ symptoms, even in those who
only had a mild acute phase. The serious, long-
term symptoms and individual morbidity rates
revealed in these support groups and consequently
shared in the media have highlighted the need for
further research to characterise Long Covid. In
May 2020, the patient-led research team of the
Body Politic COVID-19 Support Group published
the first report on Long Covid titled ‘What does
COVID-19 recovery actually look like?’ [19]. The
report was based on data from a survey of 640
members of The Body Politic COVID-19 Support
Group [19]. The survey was created and analysed
by patient-researchers and is one of the most im-
portant examples of patient activism in the field
of patient-led research. The report elucidated
the most common symptoms Long Covid as be-
ing: fatigue, chills/sweats, body aches, headaches,
brain fog-concentration challenges, gastrointesti-
nal issues, trouble sleeping, dizziness and loss of
appetite [19]. The report found over 50 symp-
toms in total and that neurological symptoms
were more common than having a cough. At
the time of the survey, 90.6% of respondents had
not yet recovered, 89% said the symptoms fluc-
tuated in intensity and frequency, and 70% saw
fluctuation in the type of symptoms, suggesting
that the recovery period may include relapses.
Many respondents reported feeling unsupported
by healthcare systems [19]. This report was effec-
tive in influencing and kick-starting Long Covid
research policy globally. The quantitative data
and analysis in the report provided convincing ev-
idence of a potential new severe long-term illness
caused by COVID-19 infection, leading to the
acknowledgement of Long Covid within medical
and academic institutions, and the expansion of
COVID-19 research policy to include studies into
this malady. The research community tested the
reproducibility of this report, and conducted re-
search to characterise Long Covid. Subsequently,
this report has been cited and largely confirmed
in scientific and medical literature [20]. The work
was engaged with by academia and major med-
ical institutions, such as the Centre for Disease
Control (CDC), the World Health Organisation
(WHO) and the National Institute for Health
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(NIH). Patients have thus defined, researched and
raised awareness of Long Covid alone. Having put
Long Covid on the global agenda, long haulers
have maintained their strong activist position to
continue to steer policy development.
Current Research
Academic and clinical research into Long Covid
has focused on characterising symptoms, their
duration and how many people suffer from Long
Covid. An Italian study of hospitalised patients
found that 87% of the sample surveyed had at
least one symptom 60 days after infection [21].
Long-term symptoms in hospitalised and non-
hospitalised patients have been recorded up to
4 months after infection [22]. In addition, 2-3
weeks after testing positive, 1 in 5 patients be-
tween the ages of 18-34 with no chronic medical
conditions had yet to return to their previous
health status [5]. This confirmed the personal ac-
counts in the support groups and the data in the
surveys: long-term symptoms from COVID-19
infection were prevalent even in healthy, young,
non-hospitalised COVID-19 patients. Some stud-
ies have indicated that women may be up to
50% more likely to experience Long Covid than
men [23, 24]. Women are also more likely to be
diagnosed with other fatigue illnesses, the rea-
sons behind this are yet to be fully elucidated
[25]. The most common symptoms from peer
reviewed studies are: fatigue, shortness of breath,
cough, joint pain and chest pain. Less common
symptoms include: cognitive impairment, depres-
sion, muscle pain, headaches and migraines, fever
and palpitations [5, 21, 26, 27]. These symptoms
are the same as those found in the patient-led
survey, but the peer-reviewed research produced
more detailed information on the more serious
symptoms indicative of organ damage. Significant
cardiac symptoms that could lead to long haulers
with cardiac issues for years afterwards have also
been documented [28–30]. Severely impaired lung
function [31, 32], acute kidney injury [33], neuro-
degenerative symptoms [26, 27, 34, 35], and psy-
chiatric issues such as depression and anxiety [26]
have also been observed and reported. For long
haulers, this research has validated their concerns
and paved the way for recognition and treatment
from medical institutions. It has also underscored
the wide range of serious symptoms associated
with Long Covid and the urgency of updated
healthcare policy.
A unique research method has emerged utilis-
ing modern technology and citizen science: the
‘COVID Symptom Study’ at King’s College Lon-
don [36]. The study recruits members of the
public as citizen scientists, recording their symp-
toms over time on the study’s app [4]. This study
showed that 10% of COVID-19 patients still have
symptoms three weeks after infection and may
continue to have them for many months [4]. The
method of the ‘COVID Symptom Study’ has since
been validated in a peer reviewed study [37], mak-
ing the study ‘an impressive demonstration of the
power of citizen science’ [38]. Importantly, this
study illustrates the power of technologically en-
abled citizen science for future pandemics [37].
The COVID Symptom Study can monitor the
health of a large population during a pandemic
when health resources are stretched, creating a
great tool for population health management dur-
ing pandemics, whilst increasing our understand-
ing of Long Covid. Citizen science has emerged
as a new and powerful tool to understand Long
Covid, the COVID-19 pandemic and future pan-
demics.
Recognising the importance of patient-led re-
search and patient activism, a second patient-led
research survey supported by researchers at Uni-
versity College London has been launched [39, 40].
Recruiting mainly from the Body Politic COVID-
19 Support Group, the second survey ‘will be
examining antibody testing results, wider and
more detailed symptoms, including neurological,
cardiovascular, systemic and beyond, as well as
the impact on mental health’ [40]. Following on
from the success of the first report, a similar
symptom survey was conducted by the Indiana
School of Medicine and Survivor Corps (another
COVID-19 support network) [41]. The patient
support groups have been a significant source of
participants for research studies [42].
Research thus far has revealed that a minority of
COVID-19 patients have multi-organ symptoms
that relapse and remit over many months, leaving
individuals with a worsened quality of life. Most
studies have concluded that more research and a
multidisciplinary approach including immunology,
cardiology, vascular biology, nephrology, respira-
4 Cambridge Journal of Science & Policy, Vol 2 (2021), Issue 1
Patients and Patient Activism in the Development of Long COVID Policy
tory medicine, hepatology, neurology, endocrinol-
ogy, rheumatology and gastroenterology, is neces-
sary for clinical research and treatment of long
haulers [26, 43]. The precise prevalence of Long
Covid patients continues to be researched glob-
ally, with differing estimates of the rate of Long
Covid amongst those who have been infected.
Future Research
Though research on characterising Long Covid
and long haulers is progressing, research into the
pathophysiology of Long Covid is limited and in
its very early stages. There is a scientific consen-
sus that Long Covid is most likely explained by
a combination of direct damage by SARS-CoV-2
and other effects mediated by the immune system
[44]. These immune mediated effects are hypoth-
esised to be the result of an aberrant immune re-
sponse or latent virus in immune privileged sites;
such as the central nervous system. An aberrant
immune response is when the body’s immune sys-
tem reacts in an uncoordinated and dysregulated
manner to infection or autoimmunity. Cytokines
are small proteins which coordinate the immune
response and inflammation, when there are ex-
cessive levels of cytokines hyper-inflammation
(cytokine storm) occurs which can cause serious
damage to the patient. Funded research policy
focusing on understanding the immunological ba-
sis of Long Covid is required to develop effective
therapeutics, clinical strategies and management
strategies.
Long-term funded research studies are an im-
portant component of research policy for Long
Covid. In the respiratory diseases SARS (Severe
Acute Respiratory Syndrome) and MERS (Mid-
dle East Respiratory Syndrome), a long tail of
symptoms were noted [45], but there was a lack of
adequately funded, long-term, follow-up studies.
In one study, it was noted that within a SARS
survivor cohort, 40% of patients had fatigue and
40% had psychiatric symptoms over 3 years after
initial infection [46]. The lack of long-term stud-
ies has denied the scientific community important
understanding into the long-term symptoms of
viral infections and the immunological mecha-
nisms involved [26]; information that would have
been very useful during this pandemic. Long-
term studies are incredibly important, not just
for current and future long haulers, but to ensure
an understanding of the biological mechanisms
behind these conditions and how to manage them
for future respiratory illnesses and pandemics.
Some long and medium term studies have been set
up, including The Post-hospitalisation COVID-19
Study (PHOSP-COVID) in the UK which will fol-
low 10,000 hospitalised COVID-19 patients over
the course of a year [47]. The ADAPT study
at the Kirby Institute in Australia also follows
individuals with COVID-19 (hospitalised and non-
hospitalised) over at least a year [48]. The NIH
and University of California, San Francisco, also
have ongoing longitudinal studies on Long Covid
[49, 50]. Currently there are approximately 45
Long Covid research projects globally, out of over
5,000 COVID-19 related projects [51], illustrating
the need for more research into Long Covid.
There is a recurring theme in both long-term and
cohort studies of over-representation of hospi-
talised patients, despite it being established that
both hospitalised and non-hospitalised COVID-19
patients can get Long Covid [17]. Research policy
needs to include the non-hospitalised group, in
addition to those who were infected with SARS-
CoV-2 particularly during the first wave, but
were never tested and are now experiencing Long
Covid. This latter group, in particular, makes
up a lot of the online support groups, but is
highly underrepresented in research. Support
groups have continued their advocacy to ensure
that all long haulers are included in the emergent
research policies [17, 18]. When patient demo-
graphics are not included or are underrepresented
in research, studies may misrepresent the nature
of Long Covid and long haulers. Policy made
from this research may not meet the needs of all
those affected.
As academic and clinical research into Long Covid
continues, support groups have maintained their
role of guiding research policy. The Long Covid
Support Group collaborated with two interna-
tional pandemic-focused organisations to hold a
Long Covid joint research forum in December
2020 [52]. The first of these organisations, the
Global Research Collaboration for Infectious Dis-
ease Preparedness (GloPID-R), is an international
network of major research funding organisations
set up to facilitate rapid and effective responses to
pandemics [53].The second organisation, the Inter-
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national Severe Acute Respiratory and emerging
Infection Consortium (ISARIC), is a global net-
work of clinical researchers, created to deal with
respiratory pandemics [54]. This collaboration
is indicative of the global importance currently
being placed on Long Covid. The forum objec-
tives were ‘to gain a better understanding of Long
Covid; the science and the personal impact’ and
‘to define research gaps for funders and researchers
to take forward’ [52]. The forum brought together
clinicians, researchers, patient support groups, in-
ternational networks and organisations such as
the WHO, as well as government representatives
to create a coordinated strategic research policy
agenda [52]. As the numbers of long haulers con-
tinue to rise, defining and pushing this research
agenda is of increasing importance.
Healthcare Policy
As research and our understanding of Long Covid
has developed, it has enabled governments and
medical institutions to begin developing and en-
acting Long Covid health policy. ‘Only with an
understanding of the prevalence of Long Covid
and the chronic health consequences of SARS-
CoV-2 infection, will it be possible to determine
the true impact of the pandemic and to adapt
healthcare to effectively diagnose, monitor and
treat patients over the long term’ [6]. Many gov-
ernments and medical institutions have taken on
board the recommendations from Long Covid re-
search, including the creation of multi-disciplinary
Long Covid Clinics [5, 26, 27]. In the UK, the Na-
tional Health Service (NHS) has launched a net-
work of more than 60 Long Covid specialist clin-
ics to help long haulers manage their persistent
symptoms [55]. The NHS has also ‘launched a
new taskforce with patients, charities, researchers
and clinicians, to help manage the NHS approach
to ‘Long Covid’ and produce information and
support materials for patients and healthcare pro-
fessionals to develop a wider understanding of
the condition’ [56] . The inclusion of patients
in this taskforce demonstrates the recognition
of the important role they play in Long Covid
awareness and policy. Post-Covid-19 care cen-
tres are opening at academic medical centres in
the United States, bringing together multidisci-
plinary teams to provide a comprehensive and
coordinated treatment to COVID-19 aftercare
[57]. There are currently Long Covid clinics in
30 out of the 50 states in the US [58], includ-
ing the Centre for Post-COVID care at Mount
Sinai hospital [59] and the Post-COVID assess-
ment and Recovery Clinic at Penn Medicine [60].
Clinics are also opening in Canada [61] and Eu-
rope [62]. Long Covid clinics in the UK, Europe
and Canada are the result of healthcare policy
implementation, based on the recommendations
of research.
The opening of clinics has resulted in The Long
Covid Support Group evolving to take on an inde-
pendent oversight role. The Long Covid Support
Group are currently running surveys on patient
experiences of the new Long Covid clinics in Eng-
land [63]. Anecdotal evidence so far suggests that
the dismissal of patients and their symptoms, as
seen in the beginning of 2020, still remains a prob-
lem in Long Covid healthcare [63] and remains a
core challenge of healthcare policy globally. This
highlights the continuing need to raise awareness
and understanding of Long Covid symptoms in
the medical community.
Future Challenges and Policy
Needs
Research studies have illuminated the symptoms,
extent and nature of Long Covid and research
policy is transitioning into long-term studies and
more detailed analysis of the exact physiology,
pathophysiology and biological mechanisms be-
hind Long Covid. This will lead to new clinical
management strategies and therapeutics (a clin-
ical treatment or drug); for long haulers. For
the first and second wave of long haulers, the
outcomes of this research are unlikely to benefit
them as the research is far from findings that will
improve their quality of life. Research has helped
inform and guide healthcare policy with the cre-
ation of Long Covid clinics. Long Covid clinics
are not present in all countries where long haulers
may reside, and they have limited capacity. The
clinics do offer some support and benefit to cur-
rent long haulers, including coordinated treat-
ment of a patient’s individual symptoms. While
not curing or treating the immunological root
of Long Covid, these coordinated symptomatic
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treatments may improve a long hauler’s quality
of life. The other main way that policy can sup-
port long haulers is through government based
socio-economic policy.
Long haulers are suffering from serious symptoms
that are directly worsening their quality of life and
ability to participate in society. ‘Doctors are now
concerned that the pandemic will lead to a sig-
nificant surge of people battling lasting illnesses
and disabilities’ [64]. The current morbidity of
Long Covid is such that most long haulers are
unable to contribute to society and their commu-
nities as they did previously [65]. For most, this
means they are unable to work at their previous
productivity rates or are completely incapable
of working, with basic everyday tasks becoming
a challenge. The stress of being unable to work
or perform basic tasks can exacerbate symptoms.
Governments need socio-economic policies such
as expanded disability support systems to sup-
port these individuals in their lives and to facil-
itate their convalescence and recovery and stop
widening health inequalities [52]. Immunologist
Dr Danny Altmann estimates ‘we probably have
way more than five million people on the planet
with Long Covid’ [51]. These are individuals who
currently and will in the future place increasing
burden on health and socio-economic systems.
Substantial population morbidity is likely in the
near and long future [65]. Population morbidity
stems from individuals’ decreased capacity for
action and increased care requirements. Serious
organ symptoms and damage are likely to lead to
much higher levels of cardiac, respiratory, kidney
and neurological issues in populations, including
potentially increased early onset Parkinson’s dis-
ease [66]. The onset of these increased healthcare
requirements will, for developed nations, coincide
with an ageing population, thus the necessity to
increase the capacity of healthcare services is piv-
otal. Screening long haulers and acute COVID-19
survivors for cardiac, lung, kidney and neurologi-
cal damage and markers now, will allow preven-
tative medical treatment, delaying and deterring
future serious illness. Increasing research funding
for conditions such as Parkinson’s disease will
enable healthcare systems to better manage the
oncoming ageing and long hauler populations. It
is important to set up and expand existing health,
disability and socio-economic support systems as
soon as possible to minimise the population-wide
effects of Long Covid.
Conclusion
Long Covid was characterised by long haulers
through online forums. Long Covid research pol-
icy and healthcare policy has and continues to be
strongly influenced by patients and their support
groups. The adoption and use of the patient term
‘Long Covid’ in research and healthcare indicates
the patient roots of the illness, as well as how
research has built on the foundations of patient
action. Long Covid has also seen the emergence
of new styles of research policy, where patients
play a more active role as participants, citizen
scientists and researchers. Integrated research
shows great promise for dealing with the health
problems of the future, emerging global diseases
and future pandemics. Policy for Long Covid
needs to continue to be developed and enacted to
meet the challenges of current and increasing pop-
ulation morbidity. We need research to improve
clinical strategies, healthcare, and socio-economic
policies for the future and to support the needs
of both current and future long haulers.
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